Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients | Synapse
April 25, 2026
Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients
Key Points
The central aim is to evaluate the clinical efficacy of pharmacogenomic-guided treatment in schizophrenia patients.
Investigated hospitalized patients diagnosed with schizophrenia.
Applied combinatorial pharmacogenomics (CPGx) to guide treatment decisions.
Significant improvement in treatment outcomes with CPGx guidance in schizophrenia patients.
Abstract
Our findings demonstrate that CPGx significantly improves treatment outcomes in hospitalized patients with schizophrenia, supporting that CPGx can guide treatment.